The incorporation of anti-BCR-ABL tyrosine kinase inhibitors (TKIs) into the treatment landscape for chronic myeloid leukemia (CML) has positively altered patients’ long-term survival [1,2]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.